BGNE240920P195000
- 5.50
- +4.95+900.00%
BeiGene Newsroom
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $198
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
BeiGene (688235): Active expansion of overseas markets can be expected
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
BeiGene Analyst Ratings
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $200
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254
TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
BeiGene (688235): The company's performance in 2024Q2 exceeded expectations and achieved profit from non-GAAP operating profits
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $198
Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential
BeiGe-U (688235): Strong growth of zebutinib, rich pipeline of new drugs
Daiwa Rating: Daiwa has raised the target price of BeiGene to HKD 162 and increased the revenue forecast for 2024-2026.
Bank Rating | CMB International: Raised Beigene's target price to $288.93 and maintained a "buy" rating and still listed as the preferred stock.
BeiGene (688235): Revenue continued to grow, adjusted profit reversed losses for the first time in the second quarter